{"id":"ion363","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Flu-like symptoms"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":{"chemblId":"CHEMBL5095463","moleculeType":"Oligonucleotide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting apoC-III expression through antisense technology, ION363 lowers triglyceride levels and improves lipid metabolism. This mechanism addresses a key driver of hypertriglyceridemia and may reduce cardiovascular events in patients with elevated triglycerides despite statin therapy.","oneSentence":"ION363 is an antisense oligonucleotide that reduces production of apolipoprotein C-III (apoC-III), a protein that impairs triglyceride clearance and increases cardiovascular risk.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:48.840Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertriglyceridemia in patients at high cardiovascular risk"}]},"trialDetails":[{"nctId":"NCT04768972","phase":"PHASE3","title":"FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2021-06-14","conditions":"Amyotrophic Lateral Sclerosis","enrollment":89}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ION363","genericName":"ION363","companyName":"Ionis Pharmaceuticals, Inc.","companyId":"ionis-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ION363 is an antisense oligonucleotide that reduces production of apolipoprotein C-III (apoC-III), a protein that impairs triglyceride clearance and increases cardiovascular risk. Used for Hypertriglyceridemia in patients at high cardiovascular risk.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}